Cytokinetics Stock Price. Everything You Need To Know About The Cytokinetics Stock!
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company’s clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv , a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten, a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-136 an novel small molecule cardiac troponin activator.
Cytokinetics Stock Price. Everything You Need To Know About The Cytokinetics Stock! performance
- Employees 409
- Company HQ South San Francisco
- Website https://cytokinetics.com/
- CYTK Asset Type Common Stock
- CYTK Market Capitalization 6.8B
- Earnings Per Share -5.45
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you interested in investing in the biopharmaceutical industry? Look no further than Cytokinetics, a leading biotech company focused on muscle biology and the development of innovative medicines. As a retail investor from Malaysia, Thailand, Indonesia, or Vietnam, you can invest in Cytokinetics through the Zorion investment platform. With Zorion’s investment insights and recommendations, you can make informed decisions about your investment in Cytokinetics. Additionally, Zorion offers a wide range of resources and educational materials to enhance your investment knowledge. Start investing in Cytokinetics today and be a part of groundbreaking advancements in the biopharmaceutical sector.
